502767-55-7

Usage

Molecular structure

The compound has a triazine ring with three amine substituents and additional cycloheptyl, ethyl-pyrrolidinyl, and 3-fluoro-4-methoxyphenyl groups attached to the nitrogen atoms.

Molecular weight

Approximately 383.48 g/mol

Potential applications

The compound has potential applications in pharmaceuticals and agrochemicals due to its structural features and functional groups that could be exploited for biological activity.

Synthesis

The synthesis of 1,3,5-Triazine-2,4,6-triaMine, N-cycloheptyl-N'-[[(2S)-1-ethyl-2-pyrrolidinyl]Methyl]-N''-(3-fluoro-4-Meth oxyphenyl)- could be of interest for researchers in the fields of organic chemistry, medicinal chemistry, and chemical engineering.

Biological activity

The compound's structural features and functional groups may contribute to its potential biological activity, making it a candidate for further research in drug discovery and development.

Solubility

The solubility of 1,3,5-Triazine-2,4,6-triaMine, N-cycloheptyl-N'-[[(2S)-1-ethyl-2-pyrrolidinyl]Methyl]-N''-(3-fluoro-4-Meth oxyphenyl)- in various solvents is not provided in the material, but it may vary depending on the specific functional groups and molecular structure.

Stability

The stability of the compound under different conditions (e.g., temperature, pH, light exposure) is not provided in the material, but it could be an important factor to consider for its potential applications.

Reactivity

The reactivity of the compound with other chemicals or biological molecules is not provided in the material, but it may be influenced by the presence of various functional groups in its structure.

Toxicity

The toxicity of the compound is not provided in the material, but it is an important factor to consider for its potential applications in pharmaceuticals and agrochemicals.

Upstream product

• 502767-47-7 6-chloro-N₂-cycloheptyl-N₄-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine 
• 22795-99-9 (S)-2-(Aminomethyl)-1-ethylpyrrolidine 
• 26116-12-1 1-ethyl-2-pyrrolidinemethanamine 
• 108-77-0 1,3,5-trichloro-2,4,6-triazine 
• 5452-35-7 cycloheptanamine 
• 366-99-4 3-fluoro-4-methoxyaniline 

Relevant academic research and scientific papers

Methods and compositions of novel triazine compounds

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Methods and compositions of novel triazine compounds

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Methods and compositions of novel triazine compounds

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Methods and compositions of novel triazine compounds

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.